

API

PRODUCT CATALOGUE 2025



COMPANY PROFILE

Pharmathen is one of the leading developers of complex drug delivery systems and advanced formulations, leveraging proprietary in-house technologies to improve patient compliance and make high-quality, affordable medicines accessible to global markets.

Today, we proudly serve a broad network of more than 250 partners in over 90 countries across Europe, North America, South America, the Middle East, Asia, Australasia, and Southern Africa. Our diverse portfolio includes over 100 products, supported by one of the industry's most extensive and advanced pipelines of Long-Acting Injectables (LAI) and other complex dosage forms, such as peptides, sustained-release oral solids, and ophthalmic formulations. These are produced in our US FDA and EU-approved manufacturing facilities in Greece and through our global contract manufacturing network.

Ranked among the top 50 pharmaceutical research companies in Europe, Pharmathen is also one of the largest private-sector investors in research and development in Greece, consistently investing close to €50 million annually. These continuous investments keep us at the forefront of innovation, enabling us to expand market access and strengthen partnerships worldwide, bringing more affordable, high-quality medicines to patients everywhere. We proudly employ more than 1,600 people representing over 24 nationalities across 9 locations. Our shared commitment to creativity, ethics, and reliability drives our vision of “making a difference in people’s lives.”

MANUFACTURING
SITE SAPES RODOPI



API PRODUCT LIST 2025

PRODUCT	INDICATION	STATUS
Aprepitant	Prevention of acute and delayed chemotherapy- induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting	EU DMF approved US DMF No 032203 Canada MF submitted DMF for S.Korea-approved
Aripiprazole	Treatment of Schizophrenia	EU DMF approved
Aripiprazole Monohydrate (sterile)	Maintenance of clinical improvement in the treatment of schizophrenia	Under development
Aripiprazole Lauroxil	Maintenance treatment of Schizophrenia in adult patients stabilized with oral aripiprazole	Under development
Brinzolamide	Ocular hypertension / Open angle Glaucoma	EU DMF approved US DMF No 034167
Cholecalciferol Concentrate (Powder Form)	Prevention and treatment of vitamin D deficiency	EU DMF approved
Clopidogrel besylate	Acute Coronary Syndrome	EU DMF approved
Dimethyl fumarate	Immunomodulator	US DMF No 030938 EU DMF approved
Febuxostat	Chronic management of Hyperuricemia	EU DMF approved
Ibandronate sodium monohydrate	Treatment and Prevention of Postmenopausal Osteoporosis	EU DMF approved J DMF available Brazil DMF available

PRODUCT	INDICATION	STATUS
Iron Sucrose	Iron replacement indicated for the treatment of iron deficiency anaemia (IDA) in patients with chronic kidney disease (CKD)	Under development
Linezolid Form I	Infection treatment	EU DMF approved
Nusinersen Sodium	Treatment of spinal muscular atrophy	Under development
Paliperidone	Treatment of Schizophrenia	EU DMF available US DMF No 31062
Paliperidone palmitate (sterile)	Treatment of Schizophrenia	Under development
Pregabalin	Management of neuropathic pain	EU DMF approved JDMF submitted
Ropinirole hydrochloride	Parkinson's Treatment	EU DMF approved
Patisiran Sodium	Treatment of Polyneuropathy	Under development
Tolterodine tartrate	Treatment of Overactive bladder	CEP valid
Valganciclovir hydrochloride	Treatment of Cytomegalovirus (CMV) Retinitis	EU DMF approved China DMF available US DMF No 031546
Vildagliptin	Antidiabetic	EU DMF approved
Voriconazole	Treatment of Invasive Aspergillosis fungal infection	EU DMF approved US DMF No 031545

DISCLAIMER

This catalogue may contain information on worldwide products and services some of which are not available in every region/country. A reference to a product or service in this catalogue does not imply that such product or service will be available in your region/country. Please consult Pharmathen for any information concerning the products and services currently available in your region / country.

Furthermore the information provided in this catalogue including any reference to any product is for informational purposes only and does not constitute an offer for sale or should not be construed as representing an offer to sell such product. You should not construe anything in this catalogue as a promotion or advertisement for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence.

The present catalogue only relates to 2025 and replaces any previous version.



